V
39.00
-0.87 (-2.18%)
| Previous Close | 39.87 |
| Open | 39.35 |
| Volume | 1,603,944 |
| Avg. Volume (3M) | 1,030,885 |
| Market Cap | 3,191,416,832 |
| Price / Sales | 671.45 |
| Price / Book | 29.28 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2024 |
| Operating Margin (TTM) | -694.43% |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 93.73% |
| Current Ratio (MRQ) | 13.03 |
| Operating Cash Flow (TTM) | -103.77 M |
| Levered Free Cash Flow (TTM) | -60.08 M |
| Return on Assets (TTM) | -28.05% |
| Return on Equity (TTM) | -78.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Verona Pharma plc | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.85% |
| % Held by Institutions | 88.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 74.00 (Wells Fargo, 89.74%) | Buy |
| Median | 57.00 (46.15%) | |
| Low | 42.00 (HC Wainwright & Co., 7.69%) | Buy |
| Average | 57.00 (46.15%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 42.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth MKM | 10 Jan 2025 | 68.00 (74.36%) | Buy | 45.20 |
| Truist Securities | 08 Jan 2025 | 57.00 (46.15%) | Buy | 46.20 |
| Wells Fargo | 08 Jan 2025 | 74.00 (89.74%) | Buy | 46.20 |
| 05 Nov 2024 | 64.00 (64.10%) | Buy | 38.39 | |
| Canaccord Genuity | 05 Nov 2024 | 44.00 (12.82%) | Buy | 38.39 |
| HC Wainwright & Co. | 05 Nov 2024 | 42.00 (7.69%) | Buy | 38.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jan 2025 | Announcement | Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights |
| 19 Nov 2024 | Announcement | Verona Pharma Announces December 2024 Investor Conference Participation |
| 05 Nov 2024 | Announcement | Verona Pharma to Present at Jefferies London Healthcare Conference |
| 04 Nov 2024 | Announcement | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 21 Oct 2024 | Announcement | Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |